Skip to main content
OpenTrials
Completed

NCT Number: NCT06571448

Efficacy, Safety, and Tolerability of SR750 in Patients With Trigeminal Neuralgia

The goal of this clinical trial is to evaluate the efficacy，safety and tolerability of SR750 in patients with trigeminal neuralgia (TN). Patients will receive SR750 (study drug) or placebo for 6 weeks and keep a diary of daily pain. The study duration for each patient is up to 11 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Trigeminal Neuralgia Cranial Nerve Diseases Facial Nerve Diseases Facial Neuralgia Mouth Diseases Nervous System Diseases Stomatognathic Diseases Trigeminal Nerve Diseases

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

China-Japan Friendship Hospital

Beijing, China

About this study

This is a phase 2, randomized, double-blind study comparing SR750 with placebo in patients with trigeminal neuralgia. It consists of a screening period, a double-blind treatment period, and a post-treatment safety follow-up period. Baseline pain intensity and number of paroxysms will be taken in the run-in period of screening period and will be checked for eligibility. Around 162 eligible subjects will be recruited and randomized into three arms at 1:1:1 ratio to receive SR750 high dose twice a day (BID) , SR750 low dose BID or placebo BID for 6 weeks. Subjects, investigators, all clinical study site staffs, and the Sponsor will remain blinded to treatment assignment during the study. Subjects will be asked to record the number of paroxysms of pain, severity of daily average pain of paroxysms and severity of daily worst pain in e-diary over the last 24 hours every night before going to bed. After completion of double-blind period, subjects will continue to complete the safety follow-up.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Diagnosis of trigeminal neuralgia as per International Classification of Headache Disorders third version (ICHD-3) criteria
  • Subjects must have experienced ≥3 paroxysms per day with a daily average pain sore of ≥4 and ≤8 on PI-NRS during the five days prior to randomization.
  • Willing and able to undergo washout of prohibited medication as per protocol requirements and refrain from use of the prohibited medication throughout the study period.
  • Female subjects must be non-pregnant and non-lactating.

Key Exclusion Criteria:

  • Secondary trigeminal neuralgia
  • Painful trigeminal neuropathies
  • Other pains that cannot be clearly differentiated from the pain associated with TN or may interfere with the pain assessment
  • Subjects have previously undergone microvascular decompression (MVD), sensory rhizotomy of trigeminal nerve, radiofrequency ablation (RFA), percutaneous balloon compression (PBC), permanent lesion of trigeminal semilunar ganglion, botulinum toxin type A for the treatment of TN within 6 months prior to screening. Subjects with severe complication after therapeutic procedure would also be excluded.
  • Known history of human immunodeficiency virus (HIV) or active infection of hepatitis B virus (HBV), hepatitis C virus (HCV) or Treponema Pallidum

Treatment and study plan

SR750 tablet

Drug

SR750 high dose BID orally for 6 weeks

Placebo

Drug

Placebo

Primary outcomes

  1. Daily Average Pain Score (DAPS)

    Time frame: up to week 6

    Change from baseline to week 6 in the weekly average of the daily average pain score (DAPS) of paroxysms using pain intensity numerical rating scale (PI-NRS).The PI-NRS consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst imaginable pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10.

Secondary outcomes

  1. Proportion of responders

    Time frame: up to week 6

    Proportion of subjects who meets one of the following criteria,

    • Patient Global Impression of Change (PGIC) response of "Much Improved" or "Very Much Improved" at Week 6. Subjects will select a value to represent their overall status since the start of the study on a 7-point scale of PGIC on which 1 corresponds to "very much improved", 2 corresponds to "much improved", 3 corresponds to "slightly improved" 4 corresponds to "no change", 5 corresponds to "slightly worse", 6 corresponds to "much worse", and 7 corresponds to "very much worse".
    • A reduction of ≥2 points from baseline in mean pain score at Week 6
    • A reduction of ≥30% from baseline in mean pain score at Week 6
    • A reduction of ≥50% from baseline in mean pain score at Week 6
    • A reduction of ≥30% from baseline in mean number of paroxysms at Week 6
    • A reduction of ≥50% from baseline in mean number of paroxysms at Week 6
    • A reduction of ≥30% from baseline in mean worst pain score at Week 6

  2. Mean pain score by week

    Time frame: up to week 6

    Change from baseline in weekly mean pain score. The daily pain score will be measured by PI-NRS described as above.

  3. Mean worst pain score by week

    Time frame: up to week 6

    Change from baseline in mean worst pain score by week. The daily worst pain score will be measured by PI-NRS described as above.

  4. Mean number of paroxysms by week

    Time frame: up to week 6

    Change from baseline in mean number of paroxysms by week

  5. Mean continuous pain score by week

    Time frame: up to week 6

    Change from baseline in mean continuous pain score by week. The daily continuous pain score will be measured by PI-NRS described as above.

  6. Proportion of subjects with continuous pain at week 6

    Time frame: up to week 6

    Change of proportion from baseline

  7. Hospital Anxiety and Depression Scale (HADS)

    Time frame: up to week 6

    Change of HADS from baseline. The HADS is a self-administered questionnaire consisting of two subscales, one for anxiety (HADS-A Subscale) and the other for depression (HADS-D Subscale). Each subscale consists of 7 items, and subjects will rate each item as it applies to them 0 points = absence of anxiety or depression; 3 points = severe anxiety or depression. The HADS-A Subscale analyzes generalized anxiety states, including anxious feelings, restlessness, anxious thoughts, and panic attacks. The HADS-D Subscale focuses on states of loss of interest and reduced pleasure response (reduced enjoyment mood). Each subscale will receive a score from 0 to 21, with bigger number indicating more severe symptom.

  8. Use of rescue medication

    Time frame: up to week 7

    Including the first time to use rescue medication, total amount and proportion

Other outcomes

  1. Adverse events

    Time frame: up to week 7

    To collect the adverse events during the study

  2. Plasma concentration of SR750 and its metabolite

    Time frame: up to day 43

    To measure the plasma concentration of SR750 and its metabolite after dosing

Sponsors and collaborators

Lead sponsor

Shanghai SIMR Biotechnology Co., Ltd.

Industry

Registry information

Official study title

A Phase 2 Randomized, Double-blind and Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of SR750 in Patients With Trigeminal Neuralgia

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Aug 26, 2024
Registry last updated
Apr 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.